Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Accendatech General Information
Accendatech is a clinical-stage biopharmaceutical company developing innovative small molecule drugs targeting cancer stem cells, with a focus on brain cancers. Its lead candidate, ACT001, has completed Phase I and entered Phase II trials for indications such as diffuse intrinsic pontine glioma. The company also has several preclinical and early clinical programs targeting various cancers and fibrotic diseases. Clinical results to date suggest promise in treating difficult-to-treat brain tumors.
Contact Information
Primary Industry
Biotech
Corporate Office
Tianjin, Tianjin
China
China
Drug Pipeline
LAM561
Phase 2Key Partnerships
Accendatech Funding
No funding data available
To view Accendatech's complete valuation and funding history, request access »